all problems
progress & abundanceScience & progresshumans affected:med· updated 2026-06-09

Scientific productivity

Ideas are getting harder to find. Reverse the decline in research productivity per dollar.

The scale of it

18worsening

x more researchers needed to sustain Moore’s-law progress vs the 1970s

The capital on it

$400M/yr↗ risingunderallocated · 0.005× fair share

Capital aimed at improving how science itself works: FROs, metascience, research tooling, funding-mechanism experiments. Excludes ordinary global R&D (~$2.5T/yr) — the meta-layer steering that ocean is ~0.02% of it.

20202025

The prize at the limit

$1Tin-the-limit market cap, if the team executes perfectly

The company that 10x the rate of scientific discovery becomes the picks-and-shovels layer under every other breakthrough — drugs, materials, energy. It taxes all downstream progress, which is why the ceiling rivals the largest infrastructure firms.

comparable: a research-infrastructure monopoly (TSMC-of-science) · confidence low · a ceiling, not a forecast

The trade: demand is high, only $400M/yr of capital is flowing (0.005× its fair share), and the prize at the limit is $1T. This is a Request for Startups and a Request for Investors at once.

Whitepaper · v0.1 · open to refutation

The summary lives here. The full whitepaper walks through the four-axis ranking, existing alternatives, proposed direction, cost & scale, and suggested investors — in the spirit of Hyperloop Alpha.

Quantity · humans affected

8.1Bhumans (compound effect)

source: estimated, scientific productivity compounds across every domain

Severity · WTP / wealth

10%low

share of affected person’s wealth they would pay for a solution

Current solutions

2.5/ 10med

quality of existing solutions — low score = high opportunity

Market size · TAM

$2.5Thigh

USD / year the world is already paying

Time · OOM to impact

20ylow

order-of-magnitude horizon to civilizational-scale impact

Capital · OOM to solve

$100.0Blow

cumulative R&D + deployment + supply chain across the arc

Priority score

9

importance × urgency, 0–100

Importance

10

humans affected × severity, gated by market

Urgency

90

direction of travel + solution gap

Neglectedness

6/10

Metascience (studying and fixing how science works) is a tiny field relative to the trillions in R&D it could make more productive.

med

Tractability

5/10

Concrete experiments exist: Focused Research Organizations, fast-grant programs, and AI-driven autonomous labs.

med

Ways to help

Build

Build autonomous labs, replication infrastructure, or fast-grant rails.

Research

Work in metascience: measure and fix the bottlenecks in how science gets funded and done.

Organizations

People to follow

Three-lens scoring

welfare · copenhagen BCR
20.0× per $low
x-risk · 80k hours ITN
6.5 / 10med
utility delta · state-of-art vs physics
35%low

Bloom, Jones, Van Reenen and Webb showed research productivity across semiconductors, agriculture, and biomedicine has been falling for decades, we spend far more scientist-hours for each new idea. The meta-problem: every other quest on this list depends on scientific throughput. Focused Research Organizations, AI-assisted research, metascience reform, and funding structure changes all compound across every domain.

The success vision · 20 years horizon

If we solve this, here is the world we get.

low

Before · today

Per-researcher productivity declining for 50+ years (BTGD). Most grant time spent on paperwork. Replication crisis unresolved. New PhDs needed to maintain Moore’s-law-style progress doubling every ~7 years.

After · 20 years

Scientific output per dollar 10× higher via automated experiments, AI literature review, FROs, lottery + fast-grants reform. Trustworthy literature. New disciplines created on AI timescales.

Voices on this quest

5 thinkers
David DeutschPhysicist & Philosopher · Oxford

Progress depends on the unhindered creation of good explanations. Institutions that reward criticism outperform those that reward consensus.

The Beginning of Infinity, multiple chapters

Elon MuskEngineer & Founder · SpaceX, Tesla, Neuralink, xAI

First-principles reasoning beats reasoning by analogy. Most industries are throttled by process, not physics. The idiot-index gap is where opportunities live.

Public interviews; Walter Isaacson biography (2023)

Patrick CollisonCo-founder & CEO, Stripe · Stripe
Progress itself is understudied. By "progress," we mean the combination of economic, technological, scientific, cultural, and organizational advancement that has transformed our lives and raised standards of living over the past couple of centuries.

Research productivity has been falling for decades and we under-study the process of progress itself. Metascience and institution design matter as much as any single discovery.

We Need a New Science of Progress (Atlantic, July 2019)

Jason CrawfordFounder · Roots of Progress

We need a new philosophy of progress that makes technological and scientific advancement a positive cultural project again, not something to apologize for.

The Techno-Humanist Manifesto

Tyler CowenEconomist & Writer · George Mason, Emergent Ventures

The Great Stagnation thesis: since roughly 1973 the low-hanging fruit of science and industry has been picked. Restoring the innovation engine is the meta-problem.

The Great Stagnation (2011)

Companies on this quest

9 mapped
OpenAIprivate

Originally nonprofit research lab, now capped-profit. Safety and superalignment teams alongside capabilities work.

$157.0Bmed
Replitprivate

Browser-based coding platform. 100M+ learners worldwide; AI agent for app-building compresses learn-to-ship cycle.

$3.0Bmed
Insitroprivate

ML-driven drug discovery from Daphne Koller. Combines stem-cell biology with deep learning.

$2.5Bmed

AI-driven drug discovery. Industrializes biology through automated phenotypic screening at scale.

$2.4Bhigh

Cell programming platform. Biosecurity Division runs metagenomic surveillance and pathogen detection at scale.

$350Mhigh
Hadrianprivate

Fully automated precision-parts factories for aerospace, defense, and infrastructure. Removing labor cost from the BOM.

private · no disclosed cap

Focused Research Organization for complex human disease. Funding structure designed to outrun the NIH grant cycle.

private · no disclosed cap

Incubates Focused Research Organizations (FROs), Cultivarium, E11, LemonBay, tackling neglected-by-structure science.

private · no disclosed cap

Alphabet-spinoff applying AlphaFold-class ML to drug design. Deals with Novartis and Eli Lilly.

private · no disclosed cap

Capital funding this quest

8 allocators

Writing about this right now

full feed →

Sources